结直肠癌肝转移的分子机制及临床治疗的研究进展

doi:10.20223/j.cnki.1000-8535.2025.03.001

广州医药 ›› 2025, Vol. 56 ›› Issue (3): 288-299.DOI: 10.20223/j.cnki.1000-8535.2025.03.001

• 专家述评 • 下一篇

结直肠癌肝转移的分子机制及临床治疗的研究进展

陈泽冉, 宗芋茹, 陈汉清

首都医科大学公共卫生学院营养与食品卫生学系（北京 100069）

收稿日期:2024-10-21 出版日期:2025-03-20 发布日期:2025-04-08
通讯作者: 陈汉清,E-mail：chenhq@ccmu.edu.cn
作者简介:陈汉清首都医科大学公共卫生学院营养与食品卫生学系,教授,博士生导师。主要研究方向为聚焦消化系统衰老危险因素及代谢重编程调控机制,基于人工合成生物系统,解决消化道炎症及肿瘤等重大疾病治疗中的新理论和新技术。发表论文80余篇,其中以第一或通信作者在Mol Cancer、iMeta、Matter、Hepatology、ACS Nano等杂志发表论文40余篇。申请专利9项,授权2项。主持国自然在内的各类课题10余项,入选全球前2%顶尖科学家榜单、北京市海外高层次人才青年项目、广州市高层次人才青年后备人才、广州市高层次卫生人才医学骨干人才等。任iMeta执行副主编,JCTH和《广州医药》编委,iMeta、Exploration和HBPD INT青年编委等。担任中国转化医学联盟理事,北京市营养学会理事,中国毒理学会青年委员会常委,中国营养协会蛋白质营养与健康分会常委,中国营养学会营养流行病分会专业委员会、中国环境诱变剂学会生物标记物专业委员会、中国环境诱变剂学会环境表观遗传学专业委员会委员等。
基金资助:
国家自然科学基金面上项目（32171370）; 北京市自然科学基金-北京经济技术开发区创新联合基金前沿项目（L248075）; 广东省基础与应用基础研究基金自然科学基金项目面上项目（2022A1515010415）; 中国中医科学院科技创新工程重点协同攻关项目（CI2023C012YL）; 高水平中医医院临床研究和成果转化能力提升项目—临床科研一体化人才专项（HLCMHPP2023001）; 广州市基础研究计划市校（院）联合资助项目重大项目（2023A03J0493）

Advances in the emerging mechanisms and treatment progress on liver metastasis of colorectal cancer

CHEN Zeran, ZONG Yuru, CHEN Hanqing

Department of Nutrition and Food Hygiene,School of Public Health,Capital Medical University,Beijing 100069,China

Received:2024-10-21 Online:2025-03-20 Published:2025-04-08

摘要/Abstract

摘要： 结直肠癌（CRC）是全球第三大最常见的癌症,也是癌症相关死亡的第二大常见原因。结直肠癌肝转移（CRLM）是导致CRC患者死亡的主要原因,根治性肝切除术是目前有望治愈CRLM的唯一途径,但大部分患者不能进行根治性肝切除术。通过早期发现并进行针对性干预,能够改善患者的治疗效果及预后。文章通过综述CRLM的发病机制、诊疗现状及最新纳米诊疗方法,为深入探索高效诊疗方法提供思路。

关键词: 结直肠癌肝转移, 临床诊疗, 纳米技术

Abstract: Colorectal cancer（CRC）is the third most common cancer and the second most common cause of cancer-related death worldwide．Colorectal cancer liver metastases（CRLM）are the leading cause of death in patients with CRC．Radical hepatectomy is the only way to cure CRLM so far,while most patients cannot undergo radical hepatectomy．CRLM treatment efficacy and prognosis can be improved by early diagnosis and specialized intervention．This paper reviews the pathogenesis,diagnosis,and treatment status of CRLM and the latest nano-diagnosis and treatment methods so as to provide ideas for in-depth exploration of efficient diagnosis and treatment methods．

Key words: colorectal liver metastases, clinical diagnosis and treatment, nanotechnology

陈泽冉, 宗芋茹, 陈汉清. 结直肠癌肝转移的分子机制及临床治疗的研究进展[J]. 广州医药, 2025, 56(3): 288-299.

CHEN Zeran, ZONG Yuru, CHEN Hanqing. Advances in the emerging mechanisms and treatment progress on liver metastasis of colorectal cancer[J]. Guangzhou Medical Journal, 2025, 56(3): 288-299.

参考文献

[1] BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].Ca-cancer J Clin,2024,74(3):229-263.
[2] RUMPOLD H,NIEDERSÜß-BEKE D,HEILER C,et al.Prediction of mortality in metastatic colorectal cancer in a real-life population:A multicenter explorative analysis[J].BMC Cancer,2020,20(1):1149.
[3] STEWART C L,WARNER S,ITO K,et al.Cytoreduction for colorectal metastases:Liver,lung,peritoneum,lymph nodes,bone,brain.When does it palliate,prolong survival,and potentially cure[J].CURR PROB SURG,2018,55(9):330-379.
[4] BILLER L H,SCHRAG D.Diagnosis and treatment of metastatic colorectal cancer:A review[J].JAMA,2021,325(7):669.
[5] ECKER B L,LEE J,SAADAT L V,et al.Recurrence-free survival versus overall survival as a primary endpoint for studies of resected colorectal liver metastasis:A retrospective study and meta-analysis[J].Lancet Oncology,2022,23(10):1332-1342.
[6] QIN S,LIU G J,HUANG M,et al.The local efficacy and influencing factors of ultrasound-guided percutaneous microwave ablation in colorectal liver metastases:A review of a 4-year experience at a single center[J].Int J Hyperthermia,2019,36(1):36-43.
[7] GIANNIS D,SIDERIS G,KAKOS C D,et al.The role of liver transplantation for colorectal liver metastases:A systematic review and pooled analysis[J].Transplant Rev(Orlando),2020,34(4):100570.
[8] ZHANG N,NG A S,CAI S,et al.Novel therapeutic strategies:Targeting epithelial-mesenchymal transition in colorectal cancer[J].Lancet Oncology,2021,22(8):e358-e368.
[9] ZHAO W,DAI S,YUE L,et al.Emerging mechanisms progress of colorectal cancer liver metastasis[J]. Front Endocrinol(Lausanne),2022(13):1081585.
[10] 李丁昌,曹李,陈鹏,等.结直肠癌肝转移多阶段机制研究进展[J].中华普外科手术学杂志,2021,15(6):696-699.
[11] LIU X,TAFTAF R,KAWAGUCHI M,et al.Homophilic CD44 interactions mediate tumor cell aggregation and polyclonal metastasis in patient-derived breast cancer models[J].Cancer Discov,2019,9(1):96-113.
[12] SHARMA U,MEDINA-SAENZ K,MILLER P C,et al.Heterotypic clustering of circulating tumor cells and circulating cancer-associated fibroblasts facilitates breast cancer metastasis[J].Breast Cancer Res Treat,2021,189(1):63-80.
[13] HUANG M,CHENG L,MO S,et al.Evaluation of colorectal cancer liver metastases based on liquid biopsy combined with folate receptor- positive circulating tumor cells and HSP90[J].Front Oncol,2022(12):912016.
[14] CHANDRA R,KARALIS J D,LIU C,et al.The colorectal cancer tumor microenvironment and its impact on liver and lung metastasis[J].Cancers,2021,13(24):6206.
[15] YANG C,WEI C,WANG S,et al.Elevated CD163+ /CD68+ ratio at tumor invasive front is closely associated with aggressive phenotype and poor prognosis in colorectal cancer[J].Int J Biol Sci,2019,15(5):984-998.
[16] WANG D,WANG X,SI M,et al.Exosome-encapsulated miRNAs contribute to CXCL12/CXCR4-induced liver metastasis of colorectal cancer by enhancing M2 polarization of macrophages[J].Cancer Letters,2020(474):36-52.
[17] PALMIERI V,LAZARIS A,MAYER T Z,et al.Neutrophils expressing lysyl oxidase‐like 4 protein are present in colorectal cancer liver metastases resistant to anti‐angiogenic therapy[J].J Pathol,2020,251(2):213-223.
[18] YANG L,LIU L,ZHANG R,et al.IL-8 mediates a positive loop connecting increased neutrophil extracellular traps(NETs)and colorectal cancer liver metastasis[J].J Cancer,2020,11(15):4384-4396.
[19] JI D,SONG C,LI Y,et al.Combination of radiotherapy and suppression of tregs enhances abscopal antitumor effect and inhibits metastasis in rectal cancer[J].J Immunother Cancer,2020,8(2):e000826.
[20] KUWAHARA T,HAZAMA S,SUZUKI N,et al.Intratumoural-infiltrating CD4 + and FOXP3 + T cells as strong positive predictive markers for the prognosis of resectable colorectal cancer[J].Br J Cancer,2019,121(8):659-665.
[21] LIU X,WANG X,YANG Q,et al.Th17 cells secrete TWEAK to trigger epithelial-mesenchymal transition and promote colorectal cancer liver metastasis[J].Cancer Res,2024,84(8):1352-1371.
[22] KROEMER M,TURCO C,SPEHNER L,et al.Investigation of the prognostic value of CD4 T cell subsets expanded from tumor-infiltrating lymphocytes of colorectal cancer liver metastases[J].J Immunother Cancer,2020,8(2):e001478.
[23] GARVEY C M,LAU R,SANCHEZ A,et al.Anti-EGFR therapy induces EGF secretion by cancer-associated fibroblasts to confer colorectal cancer chemoresistance[J].Cancers,2020,12(6):1393.
[24] GANGULY D,CHANDRA R,KARALIS J,et al.Cancer-associated fibroblasts:Versatile players in the tumor microenvironment[J].Cancers,2020,12(9):2652.
[25] ZHANG R,QI F,ZHAO F,et al.Cancer-associated fibroblasts enhance tumor-associated macrophages enrichment and suppress NK cells function in colorectal cancer[J].Cell Death Dis,2019,10(4):273.
[26] DENG S,CHENG D,WANG J,et al.MYL9 expressed in cancer-associated fibroblasts regulate the immune microenvironment of colorectal cancer and promotes tumor progression in an autocrine manner[J].J Exp Clin Cancer Res,2023,42(1):294.
[27] ZHANG R,QI F,SHAO S,et al.Human colorectal cancer-derived carcinoma associated fibroblasts promote CD44-mediated adhesion of colorectal cancer cells to endothelial cells by secretion of HGF[J].Cancer Cell Int,2019,19(1):192.
[28] BORRELLI C,ROBERTS M,ELETTO D,et al.In vivo interaction screening reveals liver-derived constraints to metastasis[J].Nature,2024,632(8024):411-418.
[29] KALLURI R,LEBLEU V S.The biology,function,and biomedical applications of exosomes[J].Science,2020,367(6478):eaau6977.
[30] JIANG K,CHEN H,FANG Y,et al.Exosomal ANGPTL1 attenuates colorectal cancer liver metastasis by regulating kupffer cell secretion pattern and impeding MMP9 induced vascular leakiness[J]. J Exp Clin Cancer Res,2021,40(1):21.
[31] SUN M,SONG H,WANG S,et al.Integrated analysis identifies microRNA-195 as a suppressor of hippo-YAP pathway in colorectal cancer[J].J Hematol Oncol,2017,10(1):79.
[32] XIANG Z,HUANG G,WU H,et al.SNHG16 upregulation-induced positive feedback loop with YAP1/TEAD1 complex in colorectal cancer cell lines facilitates liver metastasis of colorectal cancer by modulating CTCs epithelial-mesenchymal transition[J].Int J Biol Sci,2022,18(14):5291-5308.
[33] YUAN M,ZHANG X,YUE F,et al.CircNOLC1 promotes colorectal cancer liver metastasis by interacting with AZGP1 and sponging miR‐212‐5p to regulate reprogramming of the oxidative pentose phosphate pathway[J].Adv Sci(Weinh),2023,10(33):2205229.
[34] TSILI A C,ALEXIOU G,NAKA C,et al.Imaging of colorectal cancer liver metastases using contrast-enhanced US,multidetector CT,MRI,and FDG PET/CT:A meta-analysis[J]. Acta Radiol,2021,62(3):302-312.
[35] LEE S,CHOE E K,KIM S Y,et al.Liver imaging features by convolutional neural network to predict the metachronous liver metastasis in stage I-III colorectal cancer patients based on preoperative abdominal CT scan[J].BMC Bioinformatics,2020,21(S13):382.
[36] YANG X,ZHANG Z,BI X.A nomogram for predicting colorectal cancer liver metastasis using circulating tumor cells from the first drainage vein[J].Eur J Surg Oncol,2024,50(10):108579.
[37] 中国医师协会外科医师分会,中华医学会外科学分会胃肠外科学组,中华医学会外科学分会结直肠外科学组,等.中国结直肠癌肝转移诊断和综合治疗指南(2023版)[J].中华消化外科杂志,2023,22(1):1-28.
[38] DAPRÀ V,AIROLDI M,BARTOLINI M,et al.Total neoadjuvant treatment for locally advanced rectal cancer patients:Where do we stand?[J].Int J Mol Sci,2023,24(15):12159.
[39] PETRELLI F,TREVISAN F,CABIDDU M,et al.Total neoadjuvant therapy in rectal cancer:A systematic review and meta-analysis of treatment outcomes[J].Ann Surg,2020,271(3):440-448.
[40] TANG W,REN L,LIU T,et al.Bevacizumab plus mFOLFOX6 versus mFOLFOX6 alone as first-line treatment for RAS mutant unresectable colorectal liver-limited metastases:The BECOME randomized controlled trial[J].J Clin Oncol,2020,38(27):3175-3184.
[41] HU H,WANG K,HUANG M,et al.Modified FOLFOXIRI with or without cetuximab as conversion therapy in patients with RAS / BRAF wild-type unresectable liver metastases colorectal cancer:The FOCULM multicenter phase II trial[J].Oncologist,2021,26(1):e90-e98.
[42] ZAIDI M Y,NUSSBAUM D P,HSU S D,et al.Hepatic artery infusion for unresectable colorectal cancer liver metastases:Palliation and conversion[J].Surgery,2023,174(2):428-430.
[43] O’LEARY M P,WANG C,SANDHU J,et al.Salvage regional therapy using hepatic artery infusion pump in unresectable chemotherapy resistant colorectal liver metastases[J].Am J Surg,2022,223(6):1151-1156.
[44] WALKER B S,BILLINGSLEY K G,SUTTON T L,et al.Hepatic arterial infusion pump chemotherapy combined with systemic therapy for patients with advanced colorectal liver metastases:Outcomes in a newly established program[J].J Surg Oncol,2022,126(3):513-522.
[45] CHEUNG T T,MA K W,SHE W H.A review on radiofrequency,microwave and high-intensity focused ultrasound ablations for hepatocellular carcinoma with cirrhosis[J].Hepatobiliary Surg Nutr,2021,10(2):193-209.
[46] RUERS T,VAN COEVORDEN F,PUNT C J A,et al.Local treatment of unresectable colorectal liver metastases:Results of a randomized phase II trial[J].J Natl Cancer Inst,2017,109(9):djx015.
[47] LIN Y-M,PAOLUCCI I,BROCK K K,et al.Image-guided ablation for colorectal liver metastasis:Principles,current evidence,and the path forward[J].Cancers,2021,13(16):3926.
[48] ABDALLA M,COLLINGS A T,DIRKS R,et al.Surgical approach to microwave and radiofrequency liver ablation for hepatocellular carcinoma and colorectal liver metastases less than 5 cm:A systematic review and meta-analysis[J].Surg Endosc,2023,37(5):3340-3353.
[49] YU J,GREEN M D,LI S,et al.Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination[J].Nat Med,2021,27(1):152-164.
[50] SANUKI N,TAKEDA A,TSURUGAI Y,et al.Role of stereotactic body radiotherapy in multidisciplinary management of liver metastases in patients with colorectal cancer[J].J Jpn J Radiol,2022,40(10):1009-1016.
[51] MURPHY T L,MURPHY K M.Dendritic cells in cancer immunology[J]. Cell Mol Immunol,2022,19(1):3-13.
[52] KIM C W,CHON H J,KIM C.Combination immunotherapies to overcome intrinsic resistance to checkpoint blockade in microsatellite stable colorectal cancer[J].Cancers,2021,13(19):4906.
[53] WANG C,SANDHU J,OUYANG C,et al.Clinical response to immunotherapy targeting programmed cell death receptor 1/programmed cell death ligand 1 in patients with treatment-resistant microsatellite stable colorectal cancer with and without liver metastases[J].JAMA Network Open,2021,4(8):e2118416.
[54] MASPERO M,SPOSITO C,VIRDIS M,et al.Liver transplantation for hepatic metastases from colorectal cancer:Current knowledge and open issues[J].Cancers,2023,15(2):345.
[55] KIM D S,YOON Y I,KIM B K,et al.Asian pacific association for the study of the liver clinical practice guidelines on liver transplantation[J].Hepatol Int,2024,18(2):299-383.
[56] KHAN F A,ALBALAWI R,POTTOO F H.Trends in targeted delivery of nanomaterials in colon cancer diagnosis and treatment[J]. Med Res Rev,2022,42(1):227-258.
[57] LI X,LIU L,FU Y,et al.Peptide-enhanced tumor accumulation of upconversion nanoparticles for sensitive upconversion luminescence/magnetic resonance dual-mode bioimaging of colorectal tumors[J].Acta Biomater,2020(104):167-175.
[58] GONG N,SHEPPARD N C,BILLINGSLEY M M,et al.Nanomaterials for T-cell cancer immunotherapy[J].Nat Nanotechnol.,2021,16(1):25-36.
[59] HAN X,SHEN S,FAN Q,et al.Red blood cell-derived nanoerythrosome for antigen delivery with enhanced cancer immunotherapy[J].Sci Adv,2019,5(10):eaaw6870.
[60] ZHOU L,ZHANG P,WANG H,et al.Smart nanosized drug delivery systems inducing immunogenic cell death for combination with cancer immunotherapy[J].Acc Chem Res,2020,53(9):1761-1772.
[61] WU S,WANG J,FU Z,et al.Matairesinol nanoparticles restore chemosensitivity and suppress colorectal cancer progression in preclinical models:Role of lipid metabolism reprogramming[J].Nano Letters,2023,23(5):1970-1980.
[62] HUANG S,DING D,LAN T,et al.Multifunctional nanodrug performs sonodynamic therapy and inhibits TGF-β to boost immune response against colorectal cancer and liver metastasis[J].Acta Biomater,2023(164):538-552.
[63] WU S,YUN J,TANG W,et al.Therapeutic m 6 A Eraser ALKBH5 mRNA-loaded exosome-liposome hybrid nanoparticles inhibit progression of colorectal cancer in preclinical tumor models[J].ACS Nano,2023,17(12):11838-11854.
[64] JING B,GAO Y,GUO F,et al.Engineering goat milk-derived extracellular vesicles for multiple bioimaging-guided and photothermal-enhanced therapy of colon cancer[J].Biomater Sci,2023,11(4):1408-1421.
[65] WEI Y,SHEN F,SONG H,et al.The challenge and opportunity of gut microbiota‐targeted nanomedicine for colorectal cancer therapy[J].IMeta,2024,3(4):e213.
[66] LI M,JIANG A,HAN H,et al.A trinity nano-vaccine system with spatiotemporal immune effect for the adjuvant cancer therapy after radiofrequency ablation[J].ACS Nano,2024,18(5):4590-4612.

结直肠癌肝转移的分子机制及临床治疗的研究进展

Advances in the emerging mechanisms and treatment progress on liver metastasis of colorectal cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

编辑推荐

Metrics

本文评价